11,794 Halozyme Therapeutics, Inc. $HALO Shares Bought by Global Retirement Partners LLC

Global Retirement Partners LLC boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 194.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,872 shares of the biopharmaceutical company’s stock after buying an additional 11,794 shares during the quarter. Global Retirement Partners LLC’s holdings in Halozyme Therapeutics were worth $1,973,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics in the 2nd quarter worth $196,540,000. Jupiter Topco LLC bought a new position in Halozyme Therapeutics in the 2nd quarter worth $105,570,000. Caisse de depot et placement du Quebec purchased a new position in Halozyme Therapeutics during the second quarter valued at $83,940,000. Finally, Congress Asset Management Co. lifted its position in Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Key Halozyme Therapeutics News

Investors following HALO have been watching these news items:

  • Positive Sentiment: HC Wainwright reaffirmed its buy rating and set a $130 price target, suggesting substantial upside from the cited share price. HC Wainwright ratings
  • Neutral Sentiment: JPMorgan raised its target to $81 from $79 but maintained a neutral rating; the new target is below the cited share price, signaling a more cautious view. JPMorgan ratings
  • Negative Sentiment: A German court overturned the preliminary injunction that had blocked Merck from offering its subcutaneous Keytruda product in Germany. Halozyme says it will pursue a permanent patent case, but the ruling removes an immediate barrier to Merck’s launch and adds uncertainty to the dispute’s potential commercial impact. Report on German court ruling

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $75,534,196.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $96.43, for a total value of $482,150.00. Following the transaction, the director owned 48,609 shares of the company’s stock, valued at $4,687,365.87. This represents a 9.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 149,226 shares of company stock worth $15,744,643 over the last ninety days. Insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on HALO shares. Citizens Jmp raised their price objective on Halozyme Therapeutics from $93.00 to $149.00 and gave the stock a “market outperform” rating in a research note on Friday, November 6th. Wedbush set a $130.00 target price on shares of Halozyme Therapeutics in a report on Friday. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Monday, November 16th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 11th. Finally, Morgan Stanley lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $105.00 to $109.00 in a research report on Wednesday, November 11th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $110.17.

Check Out Our Latest Stock Report on Halozyme Therapeutics

Halozyme Therapeutics Stock Performance

HALO opened at $91.35 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. The stock has a market capitalization of $10.41 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 0.34 and a beta of 0.92. The company has a fifty day moving average of $113.21 and a 200 day moving average of $86.03. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The business had revenue of $492.97 million for the quarter, compared to analysts’ expectations of $491.63 million. During the same quarter in the previous year, the company earned $1.72 EPS. The business’s quarterly revenue was up 39.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Featured Articles

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.